SCHEMBL5336792

SCHEMBL5336792

O=P(O)(OCc1ccc(Br)cc1)OCc1ccc(Br)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.64
AKR1C3 P42330 1/20 0.58
IDO1 P14902 2/20 0.48
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
MAOB P27338 1/20 0.46
BTN3A1 O00481 1/20 0.44
POLB P06746 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
KDM4E B2RXH2 3/20 0.42
MAPT P10636 2/20 0.42
HPGD P15428 2/20 0.42
ALDH1A1 P00352 1/20 0.42
KMT2A Q03164 3/20 0.42
SRC P12931 1/20 0.41
FFAR1 O14842 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41
SMPD1 P17405 2/20 0.41
OGG1 O15527 1/20 0.41
MEN1 O00255 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9138596 0.93 TSHR (0.79) TSHRAKR1C3IDO1RXRARXRB
SCHEMBL27541457 0.88 TSHR (0.48) TSHRAKR1C3IDO1RXRARXRB
SCHEMBL8038340 0.84 MAOB (0.47) TSHRAKR1C3IDO1RXRARXRB
SCHEMBL31326220 0.83 TSHR (0.69) TSHRAKR1C3IDO1KMT2ASRC
SCHEMBL8038337 0.79 IDO1 (0.48) TSHRIDO1RXRARXRBMAOB
SCHEMBL21749217 0.79 TSHR (0.64) TSHRAKR1C3IDO1MAOBALDH1A1
SCHEMBL9138537 0.79 TSHR (0.64) TSHRAKR1C3MAOBBTN3A1MAPT
SCHEMBL27908642 0.78 TSHR (1.00) TSHRAKR1C3ALDH1A1SRC
SCHEMBL51316 0.78 TSHR (1.00) TSHRAKR1C3ALDH1A1SRC
SCHEMBL4219700 0.77 TSHR (0.96) TSHRAKR1C3ALDH1A1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7235666-B2 Sulfonation of 3-(hydroxymethyl)-5,5-diphenylimidazolidine-2,4-dione followed by phosphating in the presence of trisubstituted aliphatic amine base and a polar aprotic solvent; anticonvulsants, antiepileptic and antiarrhythmia agent CILAG LTD. (CH) 2007-06-26 US claimed
US-7235666-B2 Sulfonation of 3-(hydroxymethyl)-5,5-diphenylimidazolidine-2,4-dione followed by phosphating in the presence of trisubstituted aliphatic amine base and a polar aprotic solvent; anticonvulsants, antiepileptic and antiarrhythmia agent CILAG LTD. (CH) 2007-06-26 US disclosed
US-20050272706-A1 Process for the preparation of sodium fosphenytoin CILAG, LTD. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272706-A1 Process for the preparation of sodium fosphenytoin FOS, DUSP5, DCPS TSHR 3700/4885AKR1C3 1482/4885IDO1 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.